GMP-conformant on-site manufacturing of a CD133⁺ stem cell product for cardiovascular regeneration.

ABSTRACT:

Background

CD133⁺ stem cells represent a promising subpopulation for innovative cell-based therapies in cardiovascular regeneration. Several clinical trials have shown remarkable beneficial effects following their intramyocardial transplantation. Yet, the purification of CD133⁺ stem cells is typically performed in centralized clean room facilities using semi-automatic manufacturing processes based on magnetic cell sorting (MACS®). However, this requires time-consuming and cost-intensive logistics.

Methods

CD133⁺ stem cells were purified from patient-derived sternal bone marrow using the recently developed automatic CliniMACS Prodigy® BM-133 System (Prodigy). The entire manufacturing process, as well as the subsequent quality control of the fi

SUBMITTER: Skorska A 

PROVIDER: S-EPMC5303262 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature